CROSS Protocol for Locally Advanced Esophageal Carcinoma
The CROSS protocol consists of weekly carboplatin (AUC 2 mg/mL per min) and paclitaxel (50 mg/m² body surface area) for 5 cycles over 23 days, with concurrent radiotherapy delivering 41.4 Gy in 23 fractions of 1.8 Gy, administered 5 days per week, followed by surgical resection. 1
Protocol Details
Chemotherapy Regimen
- Carboplatin: AUC 2 mg/mL per min, administered intravenously weekly
- Paclitaxel: 50 mg/m² body surface area, administered intravenously weekly
- Duration: 5 weekly cycles over 23 days total
Radiation Therapy
- Total dose: 41.4 Gy
- Fractionation: 23 fractions of 1.8 Gy each
- Schedule: 5 days per week (Monday through Friday)
- Concurrent: Given simultaneously with chemotherapy
Surgery
- Performed 4-6 weeks after completion of neoadjuvant chemoradiotherapy
- Goal: R0 resection with adequate lymph node dissection (minimum 16-18 nodes, preferably ≥20 nodes) 2
Evidence Supporting CROSS Protocol
The CROSS trial demonstrated superior long-term survival with neoadjuvant chemoradiotherapy plus surgery versus surgery alone. After 84 months median follow-up, median overall survival was 48.6 months (95% CI 32.1-65.1) in the CROSS group versus 24.0 months (14.2-33.7) with surgery alone (HR 0.68, p=0.003) 1.
Histology-Specific Outcomes
- Squamous cell carcinoma: Median OS 81.6 months with CROSS versus 21.1 months with surgery alone (HR 0.48, p=0.008) 1
- Adenocarcinoma: Median OS 43.2 months with CROSS versus 27.1 months with surgery alone (HR 0.73, p=0.038) 1
Pathological Response
- Pathological complete response (pCR): 50.7% in real-world practice 3, with rates ranging from 30.6-35.0% across different studies 4
- Major pathological response (mPR): 77.5% 3
Treatment Completion and Toxicity
Compliance
- 95% of patients who started neoadjuvant chemoradiotherapy completed the entire CROSS regimen 1
Acute Toxicity
- Grade ≥3 acute toxicity: 25.5% of patients 5
- Grade ≥3 hematologic toxicity: 5.5% 4
- Grade ≥3 non-hematologic toxicity: 0.8% 4
- The CROSS regimen demonstrates lower toxicity compared to conventional cisplatin/5-FU-based regimens 4
Late Toxicity
- Grade ≥3 late adverse events: 24.8%, predominantly esophageal stenosis 5
Postoperative Complications
- Anastomotic leakage: 4.2%
- Pneumonia: 15.5%
- Pulmonary complications: 17.7%
- Cardiac complications: 5.2% 6
Guideline Recommendations
Both ASCO (2020) and ESMO (2022) guidelines endorse preoperative chemoradiotherapy as a standard of care for locally advanced esophageal carcinoma. 2, 7
Specific Indications
- Adenocarcinoma: Preoperative CRT or perioperative chemotherapy are both acceptable options 2
- Squamous cell carcinoma: Preoperative CRT followed by surgery OR definitive CRT with salvage surgery for persistent disease 2, 7
- Clinical stage: T1N1M0 or T2-3N0-1M0 (resectable, locally advanced disease) 1
Important Clinical Considerations
Adjuvant Therapy for Incomplete Response
For patients with residual pathological disease (ypT1 and/or ypN1) after trimodality therapy, adjuvant nivolumab for 1 year is now recommended based on CheckMate 577 trial showing improved disease-free survival (22.4 vs 11.0 months, HR 0.69, p<0.001). PD-L1 testing is not required. 7
Alternative to CROSS for Adenocarcinoma
For patients unable to receive radiation or where perioperative chemotherapy is preferred, FLOT regimen (docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m², fluorouracil 2,600 mg/m² as 24-hour infusion) is the standard perioperative chemotherapy, given as 4 preoperative and 4 postoperative 2-week cycles 2.
Radiation Technique
Volumetric modulated arc therapy (VMAT) is associated with reduced postoperative cardiopulmonary toxicities compared to conventional techniques 6.
Survival Outcomes in Real-World Practice
Real-world data shows 3-year OS of 49.6% and PFS of 45.6%, slightly lower than the CROSS trial (58% and 51% respectively), likely due to less favorable patient characteristics in daily practice 5. Recent studies using VMAT report improved 3-year OS of 72% 6.